Bristol?s Opdivo reduces risk of death from common lung cancer
 

Bristol?s Opdivo reduces risk of death from common lung cancer
Chicago (Reuters) - Bristol-Myers Squibb Co's drug, Opdivo, improved survival for patients with the most common form of lung cancer, nearly doubling survival for those with high levels of a specific protein in their tumors compared with chemotherapy, according to clinical trial results presented on Friday.http://i2.wp.com/reuters.us.feedspor...f?resize=1%2C1
http://feeds.feedburner.com/~ff/reut...?d=yIl2AUoC8zA http://feeds.feedburner.com/~ff/reut...Gc:F7zBnMyn0Lo http://feeds.feedburner.com/~ff/reut...Gc:V_sGLiPBpWU
http://feeds.feedburner.com/~r/reute...~4/Lf4rSFgNssw